Failure of omalizumab in cholinergic urticaria

R. Sabroe
DOI: https://doi.org/10.1111/j.1365-2230.2009.03748.x
2010-06-01
Abstract:Cholinergic urticaria is one of the more common physical urticarias. Although it is often fairly mild, severe treatment‐resistant disease may occur, with significant associated disability. Omalizumab, a monoclonal IgG anti‐IgE antibody licensed for use in severe asthma, has recently been used successfully in several types of urticaria, including in one case of cholinergic urticaria. This paper reports a patient with severe cholinergic urticaria, unresponsive to antihistamines and multiple other treatments, whose disease was also unresponsive to omalizumab.
What problem does this paper attempt to address?